Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386002951> ?p ?o ?g. }
Showing items 1 to 75 of
75
with 100 items per page.
- W4386002951 endingPage "115629" @default.
- W4386002951 startingPage "115629" @default.
- W4386002951 abstract "Direct acting antiviral (DAA) therapies are effective in the treatment and management of chronic HCV infections. Glecaprevir (GLE) and pibrentasvir (PIB) are pangenotypic DAAs that are delivered alone or as a fixed-dose oral formulation to treat chronic HCV infections with or without cirrhosis. Sensitive and dynamic bioanalytical assays are needed to understand the pharmacology of GLE and PIB.Drug free K2EDTA plasma was spiked with GLE, PIB, and their internal standards. Drugs were extracted from plasma via protein precipitation, and subsequently quantified using liquid chromatography-tandem mass spectrometry (LC-MS/MS). The method was validated according to regulatory recommendations, and evaluated in remnant plasma samples from individuals prescribed GLE and PIB.The analytical measuring ranges for GLE and PIB were 0.25-2000 ng/mL and 0.25-1000 ng/mL, respectively. The method showed acceptable accuracy and precision for both DAAs. GLE and PIB in plasma were stable following six freeze thaw cycles and at room temperature for up to 67 h. All analytes were stable in whole blood incubated at room temperature for 24 h, and at 40 °C and 100% humidity for 2 h. Negligible percent matrix effects were observed for PIB and PIB-IS across the measuring range of the assay. Significant ion suppression was observed for GLE, with an average matrix effects of 27.9%. However, relative matrix effects were < 6.3% between drug and internal standard, and deemed acceptable. Assay validation assessments in alternative matrices also met acceptance criteria. Both DAAs were successfully measured in remnant plasma samples from individuals administered GLE and PIB.An LC-MS/MS method for GLE and PIB quantification in plasma has been developed and validated. The assay met acceptable performance criteria and may be used in downstream applications to characterize DAA pharmacology for HCV treatment." @default.
- W4386002951 created "2023-08-20" @default.
- W4386002951 creator A5036090579 @default.
- W4386002951 creator A5068742049 @default.
- W4386002951 creator A5082007029 @default.
- W4386002951 date "2023-10-01" @default.
- W4386002951 modified "2023-10-12" @default.
- W4386002951 title "Development and validation of a liquid chromatographic-tandem mass spectrometric assay for the quantification of the direct acting antivirals glecaprevir and pibrentasvir in plasma" @default.
- W4386002951 cites W2022069095 @default.
- W4386002951 cites W2050226999 @default.
- W4386002951 cites W2106378149 @default.
- W4386002951 cites W2133036275 @default.
- W4386002951 cites W2517875316 @default.
- W4386002951 cites W2555741771 @default.
- W4386002951 cites W2578013986 @default.
- W4386002951 cites W2588942442 @default.
- W4386002951 cites W2605753778 @default.
- W4386002951 cites W2610443003 @default.
- W4386002951 cites W2730087219 @default.
- W4386002951 cites W2765116944 @default.
- W4386002951 cites W2788216918 @default.
- W4386002951 cites W2896190011 @default.
- W4386002951 cites W2921919494 @default.
- W4386002951 cites W2929560656 @default.
- W4386002951 cites W2973442490 @default.
- W4386002951 cites W2982819257 @default.
- W4386002951 cites W3000055716 @default.
- W4386002951 cites W3012890429 @default.
- W4386002951 cites W3148649551 @default.
- W4386002951 cites W4211254655 @default.
- W4386002951 doi "https://doi.org/10.1016/j.jpba.2023.115629" @default.
- W4386002951 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37619293" @default.
- W4386002951 hasPublicationYear "2023" @default.
- W4386002951 type Work @default.
- W4386002951 citedByCount "0" @default.
- W4386002951 crossrefType "journal-article" @default.
- W4386002951 hasAuthorship W4386002951A5036090579 @default.
- W4386002951 hasAuthorship W4386002951A5068742049 @default.
- W4386002951 hasAuthorship W4386002951A5082007029 @default.
- W4386002951 hasConcept C10390740 @default.
- W4386002951 hasConcept C106487976 @default.
- W4386002951 hasConcept C137535248 @default.
- W4386002951 hasConcept C162356407 @default.
- W4386002951 hasConcept C185592680 @default.
- W4386002951 hasConcept C43617362 @default.
- W4386002951 hasConcept C64489805 @default.
- W4386002951 hasConcept C74774607 @default.
- W4386002951 hasConceptScore W4386002951C10390740 @default.
- W4386002951 hasConceptScore W4386002951C106487976 @default.
- W4386002951 hasConceptScore W4386002951C137535248 @default.
- W4386002951 hasConceptScore W4386002951C162356407 @default.
- W4386002951 hasConceptScore W4386002951C185592680 @default.
- W4386002951 hasConceptScore W4386002951C43617362 @default.
- W4386002951 hasConceptScore W4386002951C64489805 @default.
- W4386002951 hasConceptScore W4386002951C74774607 @default.
- W4386002951 hasLocation W43860029511 @default.
- W4386002951 hasLocation W43860029512 @default.
- W4386002951 hasOpenAccess W4386002951 @default.
- W4386002951 hasPrimaryLocation W43860029511 @default.
- W4386002951 hasRelatedWork W1993766329 @default.
- W4386002951 hasRelatedWork W2019919776 @default.
- W4386002951 hasRelatedWork W2044681848 @default.
- W4386002951 hasRelatedWork W2053326508 @default.
- W4386002951 hasRelatedWork W2072694519 @default.
- W4386002951 hasRelatedWork W2107027175 @default.
- W4386002951 hasRelatedWork W2185025379 @default.
- W4386002951 hasRelatedWork W2922444478 @default.
- W4386002951 hasRelatedWork W4210312647 @default.
- W4386002951 hasRelatedWork W4319827223 @default.
- W4386002951 hasVolume "235" @default.
- W4386002951 isParatext "false" @default.
- W4386002951 isRetracted "false" @default.
- W4386002951 workType "article" @default.